Συγγραφείς:
Miltiades, P.
Lamprianidou, E.
Vassilakopoulos, T.P.
Papageorgiou, S.G.
Galanopoulos, A.G.
Vakalopoulou, S.
Garypidou, V.
Papaioannou, M.
Hadjiharissi, E.
Pappa, V.
Papadaki, H.A.
Spanoudakis, E.
Tsatalas, K.
Kotsianidis, I.
Λέξεις-κλειδιά:
antianemic agent; azacitidine; granulocyte colony stimulating factor; interleukin 2 receptor alpha, aged; antigen expression; CD34+ cell; cell type; chronic myelomonocytic leukemia; controlled study; disease course; down regulation; event free survival; female; flow cytometry; follow up; human; letter; major clinical study; male; myelodysplastic syndrome; outcome assessment; overall survival; relapse; survival; treatment duration; treatment response
